[Inhibition of Group IVA Phospholipase A as a Novel Therapeutic Strategy for Nonalcoholic Steatohepatitis].

Clicks: 153
ID: 31609
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #34 of 50 articles by views in Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Nonalcoholic steatohepatitis (NASH) is a lifestyle-related disease characterized by hepatic fibrosis with the accumulation of fat and inflammation and can progress to cirrhosis or hepatocellular carcinoma. However, effective pharmacotherapeutic strategies for hepatic fibrosis in NASH remain to be established. Among the initiators of inflammation, we have been investigating the possible involvement of group IVA phospholipase A (IVA-PLA), which catalyzes the initial step in the generation of lipid mediators, including eicosanoids and lysophospholipids, in the progression of hepatic fibrosis. We have recently demonstrated that a lack of IVA-PLA alleviates hepatic fibrosis in NASH model mice fed a high-fat and high-cholesterol diet and in CCl-treated mice. CCl-induced hepatic fibrosis was also prevented by the administration of an orally active, specific IVA-PLA inhibitor even after hepatic fibrosis had developed. Based on these findings suggesting that IVA-PLA mediates the cellular responses contributing to the progression of hepatic fibrosis, we have been exploring which types of cells in the liver are involved in IVA-PLA-mediated hepatic fibrosis using cell-specific IVA-PLA knockout mice. The preliminary experimental results suggest that IVA-PLA in endothelial cells, but not monocyte-derived cells, plays a role, in part, in the hepatic stellate cell-mediated progression of hepatic fibrosis. In this paper, we discuss the possibility that IVA-PLA and/or its related molecules are candidate pharmacotherapeutic targets for NASH treatment.
Reference Key
akiba2019inhibitionyakugaku Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Akiba, Satoshi;Kawashita, Eri;Ishihara, Keiichi;
Journal Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Year 2019
DOI
10.1248/yakushi.19-00011-2
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.